Cronos

I maintain a 'strong buy' rating for Cronos, despite regulatory headwinds, due to its strong fundamentals and potential for multibagger returns. Cronos has shown positive progress with a robust cash buffer, 35% revenue growth, reduced EBITDA losses, and positive operating cash flows in FY 2024. International expansion, strategic investments, and a focus on R&D are key drivers for Cronos' sustained top-line growth and market diversification.» Mehr auf seekingalpha.com

Marijuana stocks have been facing a downward trend in the market for some time. A big reason is regulatory uncertainty and reform issues. Legislative changes, particularly in major markets like the U.S., can greatly affect how shareholders think. Additionally, oversupply in certain regions has led to falling prices, which negatively affects revenue for companies in the sector. This has created a volatile sector where the trading behavior of the most public companies is more on the low end.» Mehr auf marijuanastocks.com

TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition.» Mehr auf globenewswire.com